Reviva Pharmaceuticals, Inc. (Reviva), a privately held, clinical stage pharmaceutical company, announced that the FDA has granted Orphan Drug Designation for its clinical stage drug candidate, RP5063, for the treatment of idiopathic pulmonary fibrosis (IPF). “Obtaining the Orphan Drug Designation is a significant regulatory milestone as well as a notable achievement for Reviva, since it validates…